Fig 4.

Immune response correlates. Overall survival (OS) from histologic diagnosis for all patients for whom serum was available to test for epidermal growth factor receptor variant III (EGFRvIII) –specific antibody titers (n = 14; left) and delayed-type hypersensitivity (DTH; n = 17; right). The blue line shows patients with EGFRvIII-specific immune responses, and the gold line shows patients without EGFRvIII-specific responses. Left: The median OS for the six patients who developed EGFRvIII-specific antibody responses was 47.7 months (95% CI, 20.8 to ∞ months). For the eight patients who did not develop antibody responses, the OS was only 22.8 months (95% CI, 21.0 to 34.9 months). After adjustment for age, Karnofsky performance status, and methylguanine methyltransferase methylation, the OS from vaccination of the patients who developed antibody responses was found to be greater (hazard ratio, 0.08; 95% CI, 0.007 to 0.93; P = .043). Right: The median OS for the three patients who developed DTH responses specific for PEPvIII (a 13-amino-acid peptide with an additional terminal cysteine that spans the EGFRvIII mutation) has not been reached at 50 months. For the 14 patients who did not develop DTH responses to PEPvIII, the OS was 23.1 months (95% CI, 21.0 to 44.1 months). Patients who developed PEPvIII DTH responses had a significantly longer OS (P = .03).